ReviewMolecular therapy. Nucleic acids2026
Emerging strategies and innovations in circular RNA synthesis.
Review in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) have emerged as a promising class of therapeutic molecules distinguished by their covalently closed topology, which provides exceptional exonuclease resistance, prolonged intracellular stability, and sustained protein expression. These properties, combined with reduced innate immunogenicity and capacity for cap-independent translation, position circRNAs as attractive candidates for vaccines, oncology therapeutics, and treatments for genetic and neurological disorders. Parallel advances in chemical biology have significantly expanded the synthetic toolkit for generating circRNAs, complementing traditional enzymatic ligation and ribozyme-based approaches with efficient chemical, chemoenzymatic, and bioorthogonal circularization strategies that enable scalable production and incorporation of diverse chemical modifications. This review integrates the biological roles of circRNAs with a comparative analysis of emerging synthetic methods, highlighting their mechanistic principles, advantages, and limitations. Advances in delivery platforms and multi-omics validation further strengthen the translational potential of engineered circRNAs as next-generation RNA therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.